Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference
WALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation
(Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and
Chief Executive Officer, will present a corporate update at the Jefferies 2013
Global Healthcare Conference on Monday, June 3, 2013, at 4:30 p.m. EDT. The
conference will take place June 3-6 at the Grand Hyatt New York.
The Repligen presentation will be webcast live and can be accessed through the
Investors section of Company's website at www.repligen.com. The webcast and
slide presentation will also be archived for a period of time on the Company's
About Repligen Corporation
Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and biopharmaceutical
companies worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to separate and purify monoclonal antibody therapeutics. We also
supply several growth factor products used to increase cell culture
productivity during the fermentation stage of drug manufacturing. In addition,
we have developed and market our OPUS^® series of pre-packed "plug-and-play"
chromatography columns, and we provide test kits to ensure final product
quality. Aside from our core bioprocessing business, we have a portfolio of
clinical-stage partnering assets, including a pancreatic imaging agent in
Phase 3 development and an orphan drug candidate in Phase 1 development.
Repligen's corporate headquarters are located in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.
This press release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that statements in
this press release which are not strictly historical statements including,
without limitation, statements identified by words like "believe," "expect,"
"may," "will," "should," "seek," or "could" and similar expressions,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, risks discussed from
time to time in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update forward-looking statements,
except as required by law.
CONTACT: Sondra S. Newman
Director Investor Relations
Press spacebar to pause and continue. Press esc to stop.